Prognostic value of systemic inflammation response indexes obtained from the complete blood count in patients treated for advanced ovarian carcinoma in front line

Objective Various systemic inflammation response indexes (SIRI) have repeatedly been described as prognostic factors in ovarian cancer.

They have not been validated in prospective trials and published results are sometimes contradictory.

We aimed to explore their role in a cohort of patients diagnosed with stage III and IV ovarian cancer treated at our institution.

Methods We retrospectively examined the prognostic influence of the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), the monocyte-to-lymphocyte ratio (MLR), the red cell distribution width (RDW), and the mean platelet volume (MPV).

Results A total of 77 patients were analyzed.

NLR > 2.243 at diagnosis, NLR before primary surgery, MLR at diagnosis, PLR > 289.1 at diagnosis, and PLR at diagnosis were significant in univariate Cox regression for progression-free survival, but none of them retained their significance in the multivariate Cox regression analysis.

For overall survival, NLR >  = 2.53 at diagnosis, MLR >  = 0.245 at diagnosis, and PLR >  = 198.3 at diagnosis resulted significant in univariate COX regression; only PLR >  = 198.3 at diagnosis retained its significance in the multivariate analysis.

Conclusion In our cohort, PLR >  = 198.3 was an independent prognostic factor for worse OS.

The definitive role of SIRI in ovarian cancer has not yet been established.

If their value as prognostic factors could finally be established, they would become a simple and economical method to predict prognosis in patients with advanced ovarian cancer.

Therefore, it is time to conduct prospective, multicenter studies with larger samples to definitively establish its role in ovarian cancer, if any.